BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

817 related articles for article (PubMed ID: 10434303)

  • 1. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice.
    Gu X; Richman J; Langfelder P; Wang N; Zhang S; Bañez-Coronel M; Wang HB; Yang L; Ramanathan L; Deng L; Park CS; Choi CR; Cantle JP; Gao F; Gray M; Coppola G; Bates GP; Ranum LPW; Horvath S; Colwell CS; Yang XW
    Neuron; 2022 Apr; 110(7):1173-1192.e7. PubMed ID: 35114102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.
    Gray M; Shirasaki DI; Cepeda C; André VM; Wilburn B; Lu XH; Tao J; Yamazaki I; Li SH; Sun YE; Li XJ; Levine MS; Yang XW
    J Neurosci; 2008 Jun; 28(24):6182-95. PubMed ID: 18550760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional correlates of the pathological phenotype in a Huntington's disease mouse model.
    Gallardo-Orihuela A; Hervás-Corpión I; Hierro-Bujalance C; Sanchez-Sotano D; Jiménez-Gómez G; Mora-López F; Campos-Caro A; Garcia-Alloza M; Valor LM
    Sci Rep; 2019 Dec; 9(1):18696. PubMed ID: 31822756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcription elongation and tissue-specific somatic CAG instability.
    Goula AV; Stys A; Chan JP; Trottier Y; Festenstein R; Merienne K
    PLoS Genet; 2012; 8(11):e1003051. PubMed ID: 23209427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease.
    Laforet GA; Sapp E; Chase K; McIntyre C; Boyce FM; Campbell M; Cadigan BA; Warzecki L; Tagle DA; Reddy PH; Cepeda C; Calvert CR; Jokel ES; Klapstein GJ; Ariano MA; Levine MS; DiFiglia M; Aronin N
    J Neurosci; 2001 Dec; 21(23):9112-23. PubMed ID: 11717344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms.
    Bradford J; Shin JY; Roberts M; Wang CE; Li XJ; Li S
    Proc Natl Acad Sci U S A; 2009 Dec; 106(52):22480-5. PubMed ID: 20018729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The absence of the aryl hydrocarbon receptor in the R6/1 transgenic mouse model of Huntington's disease improves the neurological phenotype.
    Angeles-López QD; García-Lara L; Aguirre-Pineda N; Castañeda-Arellano R; Elizondo-Azuela G; Pérez-Severiano F; Segovia J
    Behav Brain Res; 2021 Jun; 408():113230. PubMed ID: 33684424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice.
    Li H; Li SH; Yu ZX; Shelbourne P; Li XJ
    J Neurosci; 2001 Nov; 21(21):8473-81. PubMed ID: 11606636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.
    Aldous SG; Smith EJ; Landles C; Osborne GF; Cañibano-Pico M; Nita IM; Phillips J; Zhang Y; Jin B; Hirst MB; Benn CL; Bond BC; Edelmann W; Greene JR; Bates GP
    Brain; 2024 May; 147(5):1784-1798. PubMed ID: 38387080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics and neuropathology of Huntington's disease.
    Reiner A; Dragatsis I; Dietrich P
    Int Rev Neurobiol; 2011; 98():325-72. PubMed ID: 21907094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An ovine transgenic Huntington's disease model.
    Jacobsen JC; Bawden CS; Rudiger SR; McLaughlan CJ; Reid SJ; Waldvogel HJ; MacDonald ME; Gusella JF; Walker SK; Kelly JM; Webb GC; Faull RL; Rees MI; Snell RG
    Hum Mol Genet; 2010 May; 19(10):1873-82. PubMed ID: 20154343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice.
    Bradford J; Shin JY; Roberts M; Wang CE; Sheng G; Li S; Li XJ
    J Biol Chem; 2010 Apr; 285(14):10653-61. PubMed ID: 20145253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice.
    Wilburn B; Rudnicki DD; Zhao J; Weitz TM; Cheng Y; Gu X; Greiner E; Park CS; Wang N; Sopher BL; La Spada AR; Osmand A; Margolis RL; Sun YE; Yang XW
    Neuron; 2011 May; 70(3):427-40. PubMed ID: 21555070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum.
    Grondin R; Kaytor MD; Ai Y; Nelson PT; Thakker DR; Heisel J; Weatherspoon MR; Blum JL; Burright EN; Zhang Z; Kaemmerer WF
    Brain; 2012 Apr; 135(Pt 4):1197-209. PubMed ID: 22252996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects on murine behavior and lifespan of selectively decreasing expression of mutant huntingtin allele by supt4h knockdown.
    Cheng HM; Chern Y; Chen IH; Liu CR; Li SH; Chun SJ; Rigo F; Bennett CF; Deng N; Feng Y; Lin CS; Yan YT; Cohen SN; Cheng TH
    PLoS Genet; 2015 Mar; 11(3):e1005043. PubMed ID: 25760041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intergenerational and striatal CAG repeat instability in Huntington's disease knock-in mice involve different DNA repair genes.
    Dragileva E; Hendricks A; Teed A; Gillis T; Lopez ET; Friedberg EC; Kucherlapati R; Edelmann W; Lunetta KL; MacDonald ME; Wheeler VC
    Neurobiol Dis; 2009 Jan; 33(1):37-47. PubMed ID: 18930147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.
    Rodriguez-Lebron E; Denovan-Wright EM; Nash K; Lewin AS; Mandel RJ
    Mol Ther; 2005 Oct; 12(4):618-33. PubMed ID: 16019264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faulty splicing and cytoskeleton abnormalities in Huntington's disease.
    Fernández-Nogales M; Santos-Galindo M; Hernández IH; Cabrera JR; Lucas JJ
    Brain Pathol; 2016 Nov; 26(6):772-778. PubMed ID: 27529534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.